Theprubicin
Donafenib
Shanghai Zhongshan HospitalSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Donafenib cohort.
Same molecule, other indications
Theprubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →